|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||14.06 - 14.17|
|52-week range||11.65 - 17.34|
|Beta (5Y monthly)||1.31|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||0.59 (4.20%)|
|Ex-dividend date||28 Apr 2021|
|1y target est||15.30|
LEVERKUSEN, Germany & EMERYVILLE, Calif., September 14, 2021--Leaps by Bayer, the impact investment arm of Bayer AG, today announced that it has co-led a USD 15 million Series A investment round in agriculture and biotechnology innovator, Andes, with Cavallo Ventures. Other new investors Builders VC, Germin8, Accelr8 and Wilson Sonsini participated, alongside existing investors KdT Ventures and Endurance.
Bayer (BAYRY) posts positive data from the phase IIb PAGANINI study which is evaluating its investigational candidate, eliapixant, in patients with refractory chronic cough.
At least a few entrepreneurs believe the fallout could outlast the trial headlines, particularly for female startup founders.